Zachary Klaassen speaks with Jie Luo about his Prostate Cancer Foundation Young Investigator Award work on androgen receptor enhanceosomes in prostate cancer. Dr. Luo explains that enhanceosomes are ...
Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...
Oliver Sartor: Hi, I'm Oliver Sartor with Uro Today, covering metastatic castration resistant prostate cancer at ASCO 2025. A real delight for me to welcome Mark Stein, associate professor at Columbia ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
James Wysock joins Zachary Klaassen to discuss improving prostate cancer diagnostics through better biopsy needle technology. Dr. Wysock highlights early experience with the SUREcore® Biopsy Needle ...
At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman discusses his team's work with Terbium-161 in the VIOLET clinical trial at Peter Mac. He explains Terbium-161 offers both beta and Auger electron ...
At the 2025 UCSF-UCLA PSMA Conference, Alfred Morgenstern discusses his work with actinium-PSMA therapy for prostate cancer. He reviews clinical programs including Mike Sathekge's work with ...
AI Applications for Simplifying Radiopharmaceutical Dosimetry Workflows "Presentation" - Irène Buvat
At the 2025 UCSF-UCLA PSMA Conference, Irène Buvat discusses how AI can simplify personalized dosimetry in radiopharmaceutical therapy, addressing the "catch-22" where complexity limits clinical use ...
At the 2025 UCSF-UCLA PSMA Conference, EmmanuelAntonarakis reviews US guidelines for PSMA-PET in prostate cancer from NCCN, SNMMI, and AUA/SUO. He notes consensus on use for biochemical recurrence and ...
Read the Full Video Transcript Neeraj Agarwal: Welcome to another UroToday episode. Here we have Dr. Umang Swami, who is a faculty in oncology division at the Huntsman Cancer Institute at the ...
Zachary Klaassen speaks with Alicia Morgans about examining the impact of PSA doubling time awareness on treatment decisions for high-risk biochemical recurrence. Dr. Morgans discusses findings from a ...
Zachary Klaassen hosts Javier Puente to discuss the PARASEC trial. Dr. Puente describes this retrospective observational study examining treatment patterns of patients who received darolutamide in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback